Atlas Trials

A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia

Clinical trial NCT02969382 · COMPLETED

Trial details

NCT number
NCT02969382
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2016-12-05
Primary completion
2018-07-31
Enrollment
245

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.